A recent study has illuminated the critical role that symbiotic biofilms comprising Bacteroides thetaiotaomicron and C. difficile play in the treatment and prevention of Clostridioides difficile infections (CDI). With the prevalence of CDI in healthcare environments remaining high, this insight into the complex microbial interplay could potentially equip healthcare professionals with improved treatment strategies.
Major public health organizations such as the Centers for Disease Control and Prevention (CDC) have noted a concerning incidence rate for CDI, with reported cases reaching 116.1 occurrences per 100,000 individuals in 2022. Many patients suffering from CDI have underlying conditions, and recent antibiotic use within the preceding 12 weeks is common among 56% of the cases.
Meanwhile, hospital onset Clostridioides Difficile Infection (HO-CDI), a leading cause of health care-associated infection in the US, demonstrates an estimated incidence of 8.3 cases per 10,000 patient-days. In the battle against CDI, professionals use an array of interventions including testing, environmental cleaning and disinfection, antimicrobial stewardship, and isolation precautions.
However, overcoming the challenges posed by the infections demands a more sophisticated understanding of the role of biofilms in recurrent infections and the effectiveness of antimicrobials, particularly, vancomycin (VAN). New findings published in Gut Microbes seek to expand professionals’ understanding of the role and the dynamics of symbiotic biofilm formation by C. difficile and B. thetaiotaomicron.
This research is key to providing healthcare professionals with a fresh perspective on CDI prevention. C. difficile and B. thetaiotaomicron have been found to form a symbiotic biofilm in the presence of vancomycin (VAN), which indicated an increased bacterial content and an ability to better tolerate simulated intestinal fluid.
These insights suggest that targeting the symbiotic relationship between these two gut microbes could enhance the efficacy of treatments involving VAN and other antimicrobials. As such, the evaluation and incorporation of gut microbiomes and symbiotic biofilms in CDI treatments seem imperative for making strides in the prevention and treatment of CDI.